Innovation supports revenue growth acceleration in Q3
. - Revenue growth for Q3 accelerated to 5.5% (CER) lifting revenue for the first nine months to EUR 416.7 million (up…
. - Revenue growth for Q3 accelerated to 5.5% (CER) lifting revenue for the first nine months to EUR 416.7 million (up…
. - Revenue for Q3 was up 4.8% at constant exchange rates (CER) driving year-to-date revenue up 1.6% at CER to EUR 417.…
. - Revenue for the second quarter was up 2.3% at constant exchange rates (CER) driving revenue for the first half to E…
Nobel Biocare announced today the continuation of its functional re-alignment program, affecting primarily the corporate…
. - Revenue for the first quarter of EUR 141.5 million was down 2.0% at constant exchange rates (CER) and down 4.1% in…
. - Revenue for the full year 2012 was up 2.0% versus prior year to EUR 580.5 million and down 2.7% at constant exchang…
. - First quarter revenue of EUR 147.6 million was -0.2% at CER and +2.8% in EUR versus prior year - Regional revenue…
. - Continued growth (CER) in North America (+6.8%) and APAC excl. Japan (+8.5%), EMEA down 3.8% with challenges in Ibe…
. - Reported revenue up 5.0% (up 1.5% at CER) to EUR 143.5 million; impacted by natural disasters in Japan - Growth m…